Hospital
Morton Hospital, a Steward Family Hospital, INC.
Morton Hospital, a Steward Family Hospital, INC. was paid $41.66M by Medicaid between Jan 2018 and Sep 2024, across 285 billing codes. Its largest line is 99283, emergency room visit (moderate) — 18% of everything it billed.
33Billing provider infoMORTON HOSPITAL, A STEWARD FAMILY HOSPITAL, INC.
TAUNTON, MA 02780
TAUNTON, MA 02780
33aNPI1598053472assigned 07/13/2011
33bProvider typeGeneral Acute Care Hospital
28Total paid$41.66M
24GClaims1,052,301
24DCodes billed285
24AFirst – last monthJan 2018 – Sep 2024
Compared with peers
Next to other General Acute Care Hospital providers in Massachusetts
Rank by total paid#26 of 66
Median peer was paid$29.11M
This provider vs. median1.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 175,625 | $8.11M | |
| 2019 | 163,928 | $5.75M | |
| 2020 | 124,919 | $4.32M | |
| 2021 | 167,306 | $6.17M | |
| 2022 | 164,988 | $6.35M | |
| 2023 | 151,081 | $6.01M | |
| 2024incomplete | 104,454 | $4.94M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 51,079 | 46,953 | $7.48M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 35,741 | 32,092 | $5.46M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 36,022 | 33,488 | $5.25M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 4.9% | 18,625 | 3,034 | $2.05M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.8% | 7,765 | 7,395 | $1.15M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.5% | 9,380 | 8,805 | $1.04M |
| S9485 | Crisis intervention mental health services, per diem | 2.2% | 1,973 | 1,796 | $932K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 6,815 | 6,546 | $851K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.9% | 2,439 | 2,231 | $804K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.7% | 13,045 | 11,974 | $692K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.6% | 1,151 | 1,121 | $661K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.4% | 16,901 | 14,666 | $591K |
273 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 4,009 | $552K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 1.3% | 606 | $526K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.2% | 9,240 | $514K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.2% | 3,326 | $491K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.1% | 591 | $452K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 3,109 | $447K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.0% | 5,979 | $434K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,002 | $416K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 8,298 | $393K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,473 | $365K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,336 | $309K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 383 | $293K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 64,498 | $290K |
| 93971 | <1% | 1,338 | $269K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,888 | $269K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 21,585 | $254K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,328 | $253K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,342 | $252K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 13,451 | $246K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 9,666 | $242K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,496 | $226K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 9,168 | $226K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,416 | $218K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 21,424 | $216K |
| G0378 | Hospital observation service, per hour | <1% | 7,362 | $214K |
| 76830 | Ultrasound, transvaginal | <1% | 2,111 | $205K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,337 | $200K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 690 | $187K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,080 | $187K |
| 76536 | <1% | 1,632 | $187K | |
| ATP14 | <1% | 21,004 | $184K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 5,313 | $153K |
| 76770 | <1% | 1,173 | $145K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,153 | $141K |
| 80053 | Comprehensive metabolic panel | <1% | 49,028 | $138K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,576 | $117K |
| 84484 | <1% | 19,851 | $111K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,879 | $107K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,905 | $107K |
| 72141 | <1% | 415 | $104K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 870 | $103K |
| 94060 | <1% | 1,245 | $101K | |
| 12001 | <1% | 482 | $97K | |
| 87428 | <1% | 1,998 | $93K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,314 | $91K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 570 | $89K |
| 73562 | <1% | 3,901 | $87K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,368 | $87K |
| 97161 | <1% | 1,516 | $83K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 566 | $80K |
| 71250 | <1% | 1,574 | $80K | |
| 76642 | <1% | 788 | $80K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 279 | $80K |
| 73630 | <1% | 4,329 | $78K | |
| 62323 | <1% | 248 | $68K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,695 | $68K |
| 81025 | <1% | 11,719 | $65K | |
| 83690 | <1% | 14,263 | $65K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,506 | $63K |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 626 | $63K |
| 74018 | <1% | 2,392 | $63K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 26,895 | $60K |
| 73221 | <1% | 200 | $58K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 21,717 | $58K |
| 64493 | <1% | 83 | $57K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 833 | $55K |
| 84703 | <1% | 9,351 | $52K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,204 | $51K |
| 83880 | <1% | 3,567 | $50K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,680 | $48K |
| 73030 | <1% | 2,834 | $48K | |
| 77080 | <1% | 913 | $45K | |
| 73610 | <1% | 3,228 | $44K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,147 | $44K |
| 72110 | <1% | 942 | $44K | |
| 84600 | <1% | 4,170 | $43K | |
| 71271 | <1% | 1,197 | $43K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 41 | $42K |
| 94729 | <1% | 1,212 | $41K | |
| 94726 | <1% | 964 | $41K | |
| 81001 | <1% | 19,520 | $40K | |
| 64483 | <1% | 65 | $39K | |
| 93017 | <1% | 401 | $39K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,594 | $38K |
| 90715 | <1% | 1,831 | $38K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,203 | $37K |
| ATP08 | <1% | 5,051 | $35K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 16,856 | $33K |
| 73130 | <1% | 2,646 | $32K | |
| 92587 | <1% | 238 | $32K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 8,511 | $31K |
| 70486 | <1% | 503 | $31K | |
| 83735 | <1% | 8,360 | $29K | |
| 73502 | <1% | 1,266 | $29K | |
| 92567 | <1% | 628 | $28K | |
| 70544 | <1% | 54 | $28K | |
| 84702 | <1% | 2,287 | $28K | |
| 73110 | <1% | 1,710 | $27K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 13 | $26K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 30 | $26K |
| 82947 | <1% | 13,278 | $25K | |
| ATP15 | <1% | 2,857 | $25K | |
| 87081 | <1% | 4,150 | $22K | |
| 81003 | <1% | 13,955 | $20K | |
| 12011 | <1% | 102 | $20K | |
| 77065 | Tomosynthesis, mammo | <1% | 262 | $20K |
| 85610 | <1% | 8,834 | $18K | |
| 82805 | <1% | 864 | $18K | |
| 71045 | Radiologic examination, chest; single view | <1% | 8,375 | $18K |
| 85379 | <1% | 2,802 | $18K | |
| 97597 | <1% | 357 | $18K | |
| 87186 | <1% | 3,169 | $16K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 9,085 | $16K |
| 72100 | <1% | 1,133 | $15K | |
| 86850 | <1% | 2,703 | $15K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 97 | $15K |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 195 | $14K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 74 | $14K |
| 80050 | General health panel | <1% | 975 | $14K |
| J2704 | Injection, propofol, 10 mg | <1% | 15,712 | $13K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 16,953 | $13K |
| 83605 | <1% | 2,709 | $13K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 42 | $13K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,877 | $12K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13,022 | $12K |
| 87040 | <1% | 2,167 | $11K | |
| 85027 | <1% | 3,293 | $11K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 15,441 | $11K |
| 88342 | <1% | 1,565 | $10K | |
| 12002 | <1% | 52 | $10K | |
| 82570 | <1% | 5,622 | $9K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,784 | $9K |
| 36415 | Collection of venous blood by venipuncture | <1% | 26,278 | $9K |
| 80179 | <1% | 1,649 | $9K | |
| 73140 | <1% | 679 | $9K | |
| 87510 | <1% | 533 | $9K | |
| 87480 | <1% | 533 | $8K | |
| 80143 | <1% | 1,773 | $8K | |
| 87660 | <1% | 533 | $8K | |
| 73564 | <1% | 423 | $8K | |
| 82728 | <1% | 1,106 | $8K | |
| 87077 | <1% | 1,833 | $8K | |
| 87807 | <1% | 736 | $7K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,714 | $7K |
| 87631 | <1% | 65 | $7K | |
| 87070 | <1% | 1,471 | $7K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,206 | $6K |
| 84466 | <1% | 920 | $6K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,196 | $6K |
| 76641 | <1% | 61 | $6K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 245 | $6K |
| 86900 | <1% | 2,989 | $6K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,516 | $6K |
| 93880 | <1% | 74 | $6K | |
| 85730 | <1% | 1,888 | $6K | |
| 85007 | <1% | 3,265 | $6K | |
| 73080 | <1% | 524 | $6K | |
| 86901 | <1% | 2,986 | $5K | |
| 87486 | <1% | 187 | $5K | |
| 80076 | <1% | 3,870 | $5K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,509 | $5K |
| 87147 | <1% | 649 | $4K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 253 | $4K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,181 | $4K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,105 | $4K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 5,199 | $4K |
| 64494 | <1% | 91 | $3K | |
| 83540 | <1% | 1,012 | $3K | |
| ATP02 | <1% | 1,950 | $3K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,246 | $3K |
| 97035 | <1% | 41 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,129 | $3K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 25 | $3K |
| 86618 | <1% | 296 | $3K | |
| 87205 | <1% | 1,240 | $3K | |
| 97014 | <1% | 34 | $3K | |
| 81513 | <1% | 38 | $3K | |
| 70491 | <1% | 40 | $3K | |
| Q3014 | Telehealth originating site facility fee | <1% | 1,591 | $3K |
| 97162 | <1% | 89 | $3K | |
| 10060 | <1% | 27 | $3K | |
| 72050 | <1% | 40 | $3K | |
| 74183 | <1% | 12 | $2K | |
| 72083 | <1% | 15 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 549 | $2K |
| 97165 | <1% | 25 | $2K | |
| 74019 | <1% | 371 | $2K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 128 | $2K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,311 | $2K |
| 92579 | <1% | 119 | $2K | |
| 82607 | <1% | 295 | $2K | |
| 73590 | <1% | 131 | $2K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,992 | $2K |
| 82550 | <1% | 1,643 | $2K | |
| 71101 | <1% | 316 | $2K | |
| 85652 | <1% | 1,082 | $2K | |
| 84145 | <1% | 296 | $2K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,235 | $2K |
| 87088 | <1% | 351 | $2K | |
| 64495 | <1% | 38 | $2K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 31 | $1K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,990 | $1K |
| 74178 | <1% | 16 | $1K | |
| 82746 | <1% | 195 | $1K | |
| 76870 | <1% | 13 | $1K | |
| 73700 | <1% | 28 | $1K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 693 | $1K |
| 87481 | <1% | 38 | $928.50 | |
| 72082 | <1% | 13 | $913.64 | |
| 88304 | <1% | 193 | $823.87 | |
| 93225 | <1% | 13 | $791.40 | |
| 86140 | <1% | 268 | $772.28 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 45 | $753.40 |
| 80164 | <1% | 153 | $720.96 | |
| 92552 | <1% | 12 | $673.96 | |
| 86666 | <1% | 56 | $639.74 | |
| 80320 | <1% | 802 | $606.28 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 82 | $596.12 |
| J3490 | Unclassified drugs | <1% | 26 | $486.01 |
| 73090 | <1% | 40 | $433.31 | |
| 74220 | <1% | 13 | $386.82 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 910 | $374.25 |
| 83550 | <1% | 86 | $306.68 | |
| 82140 | <1% | 78 | $287.79 | |
| 90674 | <1% | 48 | $259.13 | |
| 90686 | <1% | 31 | $197.14 | |
| 82150 | <1% | 44 | $187.04 | |
| 84439 | <1% | 35 | $163.62 | |
| 96376 | <1% | 1,843 | $150.54 | |
| 88312 | <1% | 50 | $141.88 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 200 | $132.90 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 366 | $111.50 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 674 | $107.41 |
| 86141 | <1% | 13 | $106.80 | |
| 84100 | <1% | 126 | $89.88 | |
| 85045 | <1% | 42 | $86.52 | |
| 80178 | <1% | 34 | $75.02 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 415 | $70.60 |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 12 | $68.88 |
| 86308 | <1% | 15 | $62.22 | |
| 82565 | <1% | 1,254 | $61.24 | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 57 | $60.23 |
| 82272 | <1% | 31 | $53.76 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,039 | $47.23 |
| 82010 | <1% | 16 | $42.20 | |
| 85651 | <1% | 19 | $40.15 | |
| 84520 | <1% | 1,209 | $37.82 | |
| 80061 | Lipid panel | <1% | 91 | $24.48 |
| 88341 | <1% | 16 | $19.22 | |
| 83615 | <1% | 48 | $12.46 | |
| 80329 | <1% | 348 | $7.73 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,917 | $6.57 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 596 | $4.77 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 567 | $0.63 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 93 | $0.38 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 730 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 270 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 116 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 177 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 282 | $0.00 |
| 80051 | 0% | 18 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 29 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 42 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 33 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 13 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 14 | $0.00 |
| 70496 | 0% | 12 | $0.00 | |
| 76377 | 0% | 12 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 224 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 164 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 49 | $0.00 |
| 82310 | 0% | 17 | $0.00 | |
| 92555 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOLLINS, MICHAEL (STEWARD HOSPITAL CFO)
Parent organizationSTEWARD MEDICAL HOLDINGS LLC
| Provider | Location | Paid |
|---|---|---|
| Fort Morgan Family Dental | Fort Morgan, CO | $434K |
| Michael H. Collins, DDS, PA | Alexandria, MN | $12K |
| Emerson Hospital | Concord, MA | $4K |
| Michael C. Collins, D.M.D., P.A. | Baltimore, MD | $677.04 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.